Corbus Pharmaceuticals Holdings (CRBP) Change in Accured Expenses (2013 - 2025)

Corbus Pharmaceuticals Holdings' Change in Accured Expenses history runs 13 years deep, the most recent figure standing at $4.9 million for Q3 2025.

• On a quarterly basis, Change in Accured Expenses rose 248.02% year-over-year to $4.9 million in Q3 2025; TTM through Sep 2025 was $5.4 million, a 1507.29% increase from a year earlier, with the FY2024 full-year figure at -$5.6 million, down 211.53% from the prior year.
• Change in Accured Expenses grew to $4.9 million in Q3 2025 per CRBP's latest filing, from $1.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.9 million in Q3 2025 and bottomed at -$4.6 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is -$49050.0 (2023), against an average of -$496804.2.
• Across the five-year window, Change in Accured Expenses slumped 484.0% in 2021 and jumped 2322.22% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at -$3.5 million in 2021, then jumped by 133.06% to $1.2 million in 2022, then soared by 198.98% to $3.5 million in 2023, then plunged by 150.03% to -$1.7 million in 2024, then soared by 382.44% to $4.9 million in 2025.
• Per Business Quant, the three latest CRBP Change in Accured Expenses figures stand at $4.9 million (Q3 2025), $1.7 million (Q2 2025), and $476000.0 (Q1 2025).